NanoViricides Inc. (NNVC) Financial Statements (2025 and earlier)

Company Profile

Business Address 1 CONTROLS DRIVE
SHELTON, CT 06484
State of Incorp. NV
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q1
6/30/2024
Q4
3/31/2024
Q3
12/31/2023
Q2
9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,797,7783,257,2405,245,3746,969,8238,149,8089,650,958
Cash and cash equivalents4,797,7783,257,2405,245,3746,969,8238,149,8089,650,958
Prepaid expense172,742258,54872,442173,282295,486280,117
Total current assets:4,970,5203,515,7885,317,8167,143,1058,445,2949,931,075
Noncurrent Assets
Property, plant and equipment7,512,4637,602,8357,746,0927,927,8818,106,6478,290,895
Intangible assets, net (including goodwill)325,308327,376329,443331,511333,578335,646
Intangible assets, net (excluding goodwill)325,308327,376329,443331,511333,578335,646
Other undisclosed noncurrent assets14,56218,9088,85914,32414,36119,183
Total noncurrent assets:7,852,3337,949,1198,084,3948,273,7168,454,5868,645,724
TOTAL ASSETS:12,822,85311,464,90713,402,21015,416,82116,899,88018,576,799
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities262,467258,795180,372339,623143,760104,863
Accounts payable      62,695
Accrued liabilities262,467258,795180,372339,623143,76042,168
Due to related parties243,881
Other undisclosed current liabilities1,096,309554,542770,702608,688390,490 
Total current liabilities:1,358,776813,337951,074948,311534,250348,744
Noncurrent Liabilities
Long-term debt and lease obligation    1,500,0001,500,000 
Long-term debt, excluding current maturities    1,500,0001,500,000 
Other undisclosed noncurrent liabilities      
Total noncurrent liabilities:   1,500,0001,500,000 
Total liabilities:1,358,776813,337951,0742,448,3112,034,250348,744
Equity
Equity, attributable to parent, including:11,464,07710,651,57012,451,13612,968,51014,865,63018,228,055
Common stock13111811711711611,666
Additional paid in capital150,838,832147,670,351147,615,441146,017,883145,946,258145,726,648
Accumulated deficit(139,374,895)(137,018,908)(135,164,431)(133,049,495)(131,080,749)(127,510,756)
Other undisclosed equity, attributable to parent99955497
Other undisclosed equity      
Total equity:11,464,07710,651,57012,451,13612,968,51014,865,63018,228,055
TOTAL LIABILITIES AND EQUITY:12,822,85311,464,90713,402,21015,416,82116,899,88018,576,799

Income Statement (P&L) (USD)

9/30/2024
Q1
6/30/2024
Q4
3/31/2024
Q3
12/31/2023
Q2
9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
Operating expenses(2,391,361)(1,908,403)(2,184,756)(2,031,591)(3,676,373)(1,810,741)
Operating loss:(2,391,361)(1,908,403)(2,184,756)(2,031,591)(3,676,373)(1,810,741)
Nonoperating income35,37453,92769,81962,845106,380107,937
Other nonoperating income35,37453,92783,13499,338106,380107,937
Interest and debt expense   (13,315)(36,493)  
Loss from continuing operations before equity method investments, income taxes:(2,355,987)(1,854,476)(2,128,252)(2,005,239)(3,569,993)(1,702,804)
Other undisclosed income (loss) from continuing operations before income taxes    36,493(938) 
Loss from continuing operations:(2,355,987)(1,854,476)(2,128,252)(1,968,746)(3,570,931)(1,702,804)
Other undisclosed net income     938 
Net loss:(2,355,987)(1,854,476)(2,128,252)(1,968,746)(3,569,993)(1,702,804)
Other undisclosed net income attributable to parent   13,315   
Net loss available to common stockholders, diluted:(2,355,987)(1,854,476)(2,114,937)(1,968,746)(3,569,993)(1,702,804)

Comprehensive Income (USD)

9/30/2024
Q1
6/30/2024
Q4
3/31/2024
Q3
12/31/2023
Q2
9/30/2023
Q1
6/30/2023
Q4
3/31/2023
Q3
Net loss:(2,355,987)(1,854,476)(2,128,252)(1,968,746)(3,569,993)(1,702,804)
Comprehensive loss, net of tax, attributable to parent:(2,355,987)(1,854,476)(2,128,252)(1,968,746)(3,569,993)(1,702,804)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: